Fenretinide: a prototype cancer prevention drug

Bibliography

• WOLBACH SB, HOWE PR: Tissue changes following deprivation of fat-soluble A vitamin. J. Exp. Med. (1925) 42:753–780.
   PubMedGoogle Scholar
• BOLLAG W: Prophylaxis of chemically induced benign and malignant epithelial tumors by vitamin A acid (retinoic acid). Eur. J. Cancer Clin. Oncol. (1972) 8:689–693.
   Google Scholar
• CLAMON GH, SPORN MB, SMITH JM, SAFFIOTTI U: Alpha- andbeta-retinyl acetate reverse metaplasias of vitamin A deficiency in hamster trachea in organ culture. Nature (1974) 250:64–66.
   PubMed Web of Science ®Google Scholar
• COHEN SM, WITTENBERG JF, BRYAN GT: Effect of avitaminosis A and hypervitaminosis A on urinary bladder carcinogenicity of N-[4-(5-nitro-2-Mry0-2-thiazolyl]formamide. Cancer Res. (1976) 36:2334–2339.
   PubMed Web of Science ®Google Scholar
• SPORN MB, DUNLOP NM, NEWTON DL, SMITH JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. (1976) 35:1332–1338.
   PubMedGoogle Scholar
• •Early discussion of chemopreventative potential of synthetic retinoids.
   Google Scholar
• HONG WK, ENDICOTT J, ITRI LM et al: 13-ris-Retinoic acid in the treatment of oral leukoplakia. N Engl. J. Med. (1986) 315:1501–1505.
   PubMed Web of Science ®Google Scholar
• •An initial clinical demonstration of the cancer chemopreventative activity of retinoids.
   Google Scholar
• MEYSKENS FL Jr, SURWIT E, MOON TE et al: Enhancement of regression of cervical intraepithelial neoplasia II (moderated dysplasia) with topically applied all-trans-retinoic acid: a randomized trial../. Natl. Cancer Inst. (1994) 86:539–543.
   PubMed Web of Science ®Google Scholar
• HONG WK, LIPPMAN SM, ITRI LM et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl. J. Med. (1990) 323:795–801.
   PubMed Web of Science ®Google Scholar
• KRAEMER KH, DIGIOVANNA JJ, MOSHELL AN, TARONE RE, PECK GL: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl. J. Med. (1988) 318:1633–1637.
   PubMed Web of Science ®Google Scholar
• MOON TE, LEVINE N, CARTMEL B et al: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidennol. Biomarkers Prey. (1997) 6:949–956.
   PubMed Web of Science ®Google Scholar
• HUANG ME, YE YC, CHEN SR et al.: Use of all- transretinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 72:567–572.
   PubMed Web of Science ®Google Scholar
• MOON RC, McCORMICK DL, BECCI PJ et al: Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis (1982) 3:1469–1472.
   PubMed Web of Science ®Google Scholar
• •Preclinical demonstration of the anticarcinogenic effect of retinamides in bladder cancer model.
   Google Scholar
• MOON RC: Comparative aspects of carotenoids and retinoids as chemopreventive agents for cancer. Nutt: (1989) 119:127–134.
   PubMed Web of Science ®Google Scholar
• SANI BP, MEEKS RG: Subacute toxicity ofall- trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide. Toxicol. Appl. Pharmacol. (1983) 70:228–235.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, HOLLISTER JL, BAGG BJ, LONG RE: Enhancement of murine hepatocarcinogenesis by all-trans-retinoic acid and two synthetic retinamides. Carcinogenesis (1990) 11:1605–1609.
   PubMed Web of Science ®Google Scholar
• MOON RC, THOMPSON HJ, BECCI PJ et al.: N-(4-Hydroxypheny0retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. (1979) 39:1339–1346.
   PubMed Web of Science ®Google Scholar
• •Preclinical demonstration of the anticarcinogenic effect of fenretinide in a breast cancer model.
   Google Scholar
• HULTIN TA, MAY CM, MOON RC: N-(4-Hydroxypheny0-all-trans-retinamide pharmacokinetics in female rats and mice. Drug Metab. Dispos. (1986) 14:714–717.
   PubMed Web of Science ®Google Scholar
• SWANSON BN, ZAHAREVITZ DW, SPORN MB: Pharmacokinetics of N-(4-hydroxypheny1)-all-trans-retinamide in rats. Drug Metab. Dispos. (1980) 8:168–172.
   PubMed Web of Science ®Google Scholar
• •Early examination of pharmacokinetic behaviour of fenretinide.
   Google Scholar
• FORMELLI F, CLERICI M, CAMPA T et al.: Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. aim Oncol. (1993) 11:2036–2042.
   PubMed Web of Science ®Google Scholar
• HULTIN TA, FILLA MS, McCORMICK DL: Distribution and metabolism of the retinoid, N-(4-methoxypheny1)-all- trans-retinamide, the major metabolite of N-(4-hydroxypheny1)-a1l-trans-retinamide, in female mice. Drug Metab. Dispos. (1990) 18:175–179.
   PubMed Web of Science ®Google Scholar
• MEHTA RG, MOON RC, HAWTHORNE M, FORMELLI F, COSTA A: Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer (1991) 27:138–141.
   PubMed Web of Science ®Google Scholar
• •Clinical demonstration of breast tissue-concentrating effect of fenretinide.
   Google Scholar
• LOTAN R: Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. (1996) 16:2415–2419.
   PubMed Web of Science ®Google Scholar
• PERGOLIZZI R, APPIERTO V, CROSTI M et al.: Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int. J. Cancer (1999) 81:829–834.
   PubMed Web of Science ®Google Scholar
• SABICHI AL, HENDRICKS DT, BOBER MA, BIRRER MJ: Retinoic acid receptor 13 expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J. Nati Cancer Inst. (1998) 90:597–605.
   PubMed Web of Science ®Google Scholar
• FANJUL AN, DELIA D, PIEROTTI MA, RIDEOUT D, QIU J, PFAHL M: 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem. (1996) 271:22441–22446.
   PubMed Web of Science ®Google Scholar
• DELIA D, AIELLO A, LOMBARDI L et al.: N-(4-Hydroxypheny0retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res. (1993) 53:6036–6041.
   PubMed Web of Science ®Google Scholar
• CLIFFORD JL, MENTER DG, WANG M, LOTAN R, LIPPMAN SM: Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyOretinamide in F9 embryonal carcinoma cells. Cancer Res. (1999) 59:14–18.
   PubMed Web of Science ®Google Scholar
• ORIDATE N, SUZUKI S, HIGUCHI M, MITCHELL MF, HONG WK, LOTAN R: Involvement of reactive oxygen species in N-(4-hydroxypheny0retinamide-induced apoptosis in cervical carcinoma cells. I Natl. Cancer Inst. (1997) 89:1191–1198.
   PubMed Web of Science ®Google Scholar
• •Demonstration of receptor-independent mechanism of fenretinide antitumour activity.
   Google Scholar
• HAIL N Jr, LOTAN R: Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyflretinamide-induced apoptosis. Cancer Epidennol. Biomarkers Prey. (2000) 9:1293–1301.
   PubMed Web of Science ®Google Scholar
• DIPIETRANTONIO AM, HSIEH T-C, JUAN G, TRAGANOS F, DARZYNKIEWICZ Z, WU JM: Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res. (2000) 60:4331–4335.
   PubMed Web of Science ®Google Scholar
• DELIA D, AIELLO A, MERONI L, NICOLINI M, REED JC, PIEROTTI MA: Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis (1997) 18:943–948.
   PubMed Web of Science ®Google Scholar
• SWANSON BN, NEWTON DL, ROLLER PP, SPORN MB: Biotransformation and biological activity of N-(4-hydroxyphenyflretinamide derivatives in rodents. J. Pharmacol. Exp. Titer. (1981) 219:632–637.
   PubMed Web of Science ®Google Scholar
• WANG TTY, PHANG JM: Effect of N-(4-hydroxyphenyflretinamide on apoptosis in human breast cancer cells. Cancer Lett. (1996) 107:65–71.
   PubMed Web of Science ®Google Scholar
• XIA Y, WONG NS, FONG WF, TIDEMAN H: Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxypheny0retinamide (4HPR). Int. J. Cancer (2002) 102(1):7–14.
   PubMed Web of Science ®Google Scholar
• LOVAT PE, OLIVERIO S, RANALLI M et al: GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res. (2002) 62(18):5158–5167.
   PubMed Web of Science ®Google Scholar
• KIM DG, YOU KR, LIU MJ, CHOI YK, WON YS: GADD153-mediated anticancer effects of N-(4-hydroxyphenyOretinamide on human hepatoma cells. J. Biol. Chem. (2002) 277(41): 38930–38938.
   PubMed Web of Science ®Google Scholar
• ZOU C, WANG L, LIEBERT M, GROSSMAN HB, LOTAN R, WEI Q: Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. Int. J. Oncol (1998) 13 (5): 1037–1041.
   PubMed Web of Science ®Google Scholar
• GRUNT TW, DITTRICH E, OFFTERDINGER M, SCHNEIDER SM, DITTRICH C, HUBER H: Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. BE J. Cancer (1998) 78:79–87.
   Web of Science ®Google Scholar
• SORIA JC, MOON C, WANG L et al: Effects of N-(4-hydroxypheny6retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. Natl. Cancer Inst. (2001) 93:1257–1263.
   Google Scholar
• ROBERSON KM, PENLAND SN, PADILLA GM et al.: Fenretinide: Induction of apoptosis and endogenous transforming growth factor 13 in PC-3 prostate cancer cells. Cell Growth Differ. (1997) 8:101–111.
   PubMedGoogle Scholar
• CIOLINO HP, WANG TTY, SATHYAMOORTHY N: Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. BL I Cancer (2000) 83:333–337.
   Web of Science ®Google Scholar
• TANABE T: Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines. Hiroshima I Med. Sci. (2000) 49:67–72.
   PubMedGoogle Scholar
• RODRIGUEZ-BURFORD C, LUBET RA, ETO I et al.: Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model. Carcinogenesis (1999) 20:71–76.
   PubMed Web of Science ®Google Scholar
• PARRETT ML, ABOU-ISSA HM, ALSHAFIE G, ROSS MS, HARRIS RE, ROBERTSON FM: Comparative ability of ibuprofen and N-(4-hydroxyphenyflretinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms. Anticancer Res. (1999) 19:5079–5085.
   PubMed Web of Science ®Google Scholar
• STEELE VE, LUBET RA, KELLOFF GJ, ETO I, JULIANA MM, GRUBBS CJ: Chemoprevention of experimental mammary cancer with combination of agents. Proc. Am. Assoc. Cancer Res. (1998) 39:197 (Abstract no. 1344).
   Google Scholar
• McCORMICK DL, RAO KVN: Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat. Eur. Urol. (1999) 35:464–467.
   PubMed Web of Science ®Google Scholar
• SPORN MB: New agents for chemoprevention of prostate cancer. Eur. Urol. (1999) 35:420–423.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, RAO KVN, DOOLEY L et al: Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxypheny6 -all- trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. (1998) 58:3282–3288.
   PubMed Web of Science ®Google Scholar
• MOON RC, KELLOFF GJ, DETRISAC CJ, STEELE VE, THOMAS CF, SIGMAN CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis (1993) 14:1487–1489.
   PubMed Web of Science ®Google Scholar
• MOON RC, KELLOFF GJ, DETRISAC CJ, STEELE VE, THOMAS CF, SIGMAN CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res. (1994) 14:5–11.
   PubMed Web of Science ®Google Scholar
• MOON RC: Chemoprevention of B(a)P-Induced Lung Tumors in Strain A Mice. University of Illinois, Chicago, IL, USA (1995) (Contract no. NO1-CN–35535–01).
   Google Scholar
• WATTENBERG L: Efficacy Studies of Chemopreventive Agents Delivered by Aerosol on Pulmonary Tumors Tumorigenesis in A/I Mice. University of Minnesota, MN, USA (1999) (Contract no. NO1-CN–75114).
   Google Scholar
• CONAWAY CC, RAO D, KELLOFF GJ, STEELE VE, RIVENSON A, CHUNG F-L: Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and 13-carotene for tobacco-nitrosamine-induced lung tumors in A/J mice. Cancer Lett. (1998) 124:85–93.
   PubMed Web of Science ®Google Scholar
• MOON RC, RAO KVN, DETRISAC CJ, KELLOFF GJ, STEELE VE, DOODY L: Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int. .1. Oncol. (1994) 4:661–667.
   PubMed Web of Science ®Google Scholar
• ZHENG Y, KRAMER PM, OLSON G et al: Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis (1997) 18:2119–2125.
   PubMed Web of Science ®Google Scholar
• GUPTA A, NINES R, RODRIGO KA, et al: Effects of dietary N-(4-hydroxyphenyl) retinamide of N-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis in the Fisher 344 rat. I Nati Cancer Inst. (2001) 93(13)990–998.
   Google Scholar
• GRUBBS CJ, ETO I, JULIANA MM, HARDIN JM, WHITAKER LM: Effect of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumors. Anticancer Res. (1990) 10:661–666.
   PubMed Web of Science ®Google Scholar
• KELLOFF G, CROWELL JA, BOONE CW et al.: Strategy and planning for chemopreventive drug development: Clinical Development Plan: N-(4-hydroxyphenyl) retinamide (4-HPR). Cellular Biochem. (1994) (Suppl. 20):176–196.
   Google Scholar
• KENEL MF, KRAYER JH, MERZ EA, PRITCHARD JF: Teratogenicity of N-(4-hydroxyphenyfl-all-trans-retinamide in rats and rabbits. 7aratogenesis Carcinog. Mutagen. (1988) 8:1–11.
   PubMedGoogle Scholar
• TURTON JA, WILLARS GB, HASELDEN JN, WARD SJ, STEELE CE, HICKS RM: Comparative teratogenicity of nine retinoids in the rat. Int. I Exp. Pathol. (1992) 73:551–563.
   PubMed Web of Science ®Google Scholar
• FORMELLI F, DE PALO G, COSTA A, VERONESI U: Human transplacental passage of the retinoid fenretinide (4HPR). Eur. J. Cancer (1998) 34:428–429.
   PubMed Web of Science ®Google Scholar
• KAISER-KUPFER MI, PECK GL, CARUSO RC, JAFFE MJ, DIGIOVANNA JJ, GROSS EG: Abnormal retinal function associated with fenretinide, a synthetic retinoid. Arch. Ophthalmol. (1986) 104:69–70.
   PubMed Web of Science ®Google Scholar
• •An early observation of fenretinide ocular toxicity in clinical studies.
   Google Scholar
• KINGSTON TP, LOWE NJ, WINSTON J, HECKENLIVELY J: Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl) retinamide therapy for psoriasis. Clin. Exp. Dermatol. (1986) 11:624–627.
   PubMed Web of Science ®Google Scholar
• MODIANO MR, DALTON WS, LIPPMAN SM, JOFFE L, BOOTH AR, MEYSKENS FL Jr: Phase II study of fenretinide (N-R-hydroxyphenyllretinamide) in advanced breast cancer and melanoma. Invest. New Drugs (1990) 8:317–319.
   PubMed Web of Science ®Google Scholar
• •Phase II study of fenretinide as a cancer therapeutic.
   Google Scholar
• FILIBERTI A, TAMBURINI M, ANDREOLI C et al: Psychologic aspects of patients participating in a Phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide. Tumori (1988) 74:353–356.
   PubMed Web of Science ®Google Scholar
• GROSS EG, PECK GL, DIGIOVANNA JJ: Adverse reaction to fenretinide, a synthetic retinoid. Arch. Dermatol. (1991) 127:1849–1850.
   PubMed Web of Science ®Google Scholar
• BERNI R, FORMELLI F: LI vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett. (1992) 308:43–45.
   PubMed Web of Science ®Google Scholar
• DECENSI A, TORRISI R, POLIZZI A et al: Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface../. Natl. Cancer Inst. (1994) 86:105–110.
   PubMed Web of Science ®Google Scholar
• STANDEVEN AM, TENG M, CHANDRARATNA RA: Lack of involvement of retinoic acid receptor alpha in retinoid-induced skin irritation in hairless mice. Toxicol. Lett. (1997) 92:231–240.
   PubMed Web of Science ®Google Scholar
• COSTA A, MALONE W, PERLOFF M et al: Tolerability of the synthetic retinoid fenretinide (HPR). Eur. I Cancer Clin. Oncol. (1989) 25:805–808.
   PubMedGoogle Scholar
• •An early clinical report of the use of fenretinide in a chemoprevention setting.
   Google Scholar
• DECENSI A, TORRISI R, BRUNO S et al: Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol. Biomarkers Prey. (2000) 9:1071–1078.
   PubMed Web of Science ®Google Scholar
• •Results of an initial clinical trial of fenretinide for the modulation of biomarkers associated with the prevention of bladder cancer recurrence.
   Google Scholar
• CHIESA F, TRADATI N, MARAZZA M et al: Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur. J. Cancer B Oral Oncol. (1992) 28B:97–102.
   PubMed Web of Science ®Google Scholar
• TRADATI N, CHIESA F, ROSSI N et al: Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Cancer Lett. (1994) 76:109–111.
   PubMed Web of Science ®Google Scholar
• SRIDHARA R, PECK G, WU S et al: Pharmacokinetics (PK) and pharmacodynamics (PD) of fenretinide (4-HPR) in patients (pts) treated in a skin cancer prevention trial. Proc. AMU. Meet. Am. Soc. Clin. Oncol. (1997) 16:540A (Abstract 1945).
   Google Scholar
• MOGLIA D, FORMELLI F, BALI VA G et al: Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Cancer Lett. (1996) 110:87–91.
   PubMed Web of Science ®Google Scholar
• PIENTA KJ, ESPER PS, ZWAS F, KRZEMINSKI R, FLAHERTY LE: Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am. J. Clin. Oncol. (1997) 20:36–39.
   PubMed Web of Science ®Google Scholar
• •Clinical exploration of utility of fenretinide for prostate cancer prevention.
   Google Scholar
• THALLER C, SHALEV M, FROLOV A et al: Fenretinide therapy in prostate cancer: Effects on tissue and serum retinoid concentration. J. Clin. Oncol. (2000) 18:3804–3808.
   PubMed Web of Science ®Google Scholar
• URBAN D, MYERS R, MANNE U et al: Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur. Urol. (1999) 35:429–438.
   PubMed Web of Science ®Google Scholar
• VERONESI U, DE PALO G, MARUBINI E et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. ./. Natl. Cancer Inst. (1999) 91:1847–1856.
   PubMed Web of Science ®Google Scholar
• ••Vanguard Phase III study on the effects offenretinide as a breast cancer chemopreventative agent.
   Google Scholar
• FORMELLI F, CAMERINI T, CAVADINI E et al.: Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome. Cancer Epidemiol. Biomarkers Prey (2003) 12:34–41.
   PubMed Web of Science ®Google Scholar
• MENARD S, CAMERINI T, MARIANI L et al: Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Nati Cancer Inst. (2001) 93:240–241.
   PubMed Web of Science ®Google Scholar
• HANKINSON SE, WILLETT WC, COLDITZ GA et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 351:1393–1396.
   PubMed Web of Science ®Google Scholar
• TORRISI R, PENSA F, ORENGO MA et al: The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res. (1993) 53:4769–4771.
   PubMed Web of Science ®Google Scholar
• TORRISI R, PARODI S, FONTANA V et al: Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. Lk. J. Cancer (1998) 76:787–790.
   PubMed Web of Science ®Google Scholar
• TORRISI R, MEZZETTI M, JOHANSSON H et al: Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-I, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial. Int. Cancer (2000) 87:601–605.
   PubMed Web of Science ®Google Scholar
• DECENSI A, TORRISI R, FONTANA V et al: Correlation between plasma transforming growth factor-I31 and second primary breast cancer in a chemoprevention trial. Eur. J. Cancer (1998) 34:999–1003.
   PubMed Web of Science ®Google Scholar
• DECENSI A, BONANNI B, OMODEI U et al: Randomized trial of fenretinide in HRT users using plasma IGF-I as a surrogate biomarker. Proc. AMU. Meeting Am. Soc. Clin. Oncol. (2000) 19 (Abstract 2456).
   Google Scholar
• BONANNI B, RAMAZZOTTO F, FRANCHI D et al: A randomized trial of fenretinide in HRT users using IGF-I as a surrogate biomarker. Breast Cancer Res. Treat. (2000) 64:48.
   Google Scholar
• DE PALO G, VERONESI U, CAMERINI T et al.: Can fenretinide protect women against ovarian cancer? J. Natl. Cancer Inst. (1995) 87:146–147.
   Google Scholar
• ••Initial proposal for the clinicalexamination of fenretinide as an ovarian cancer chemopreventative agent.
   Google Scholar
• FORMELLI F, CLERIS L: Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian xenograft and in a cisplatin-resistant sub-line. Eur. J. Cancer (2000) 36:2411–2419.
   PubMed Web of Science ®Google Scholar
• SUPINO R, CROSTI M, CLERICI M et al: Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int. J. Cancer (1996) 65:491–497.
   PubMed Web of Science ®Google Scholar
• FORMELLI F, CLERIS L: Synthetic retinoid fenretinide is effective against human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res. (1993) 53:5374–5376.
   PubMed Web of Science ®Google Scholar
• ZHANG D, HOLMES WE WU S, SOPRANO DR, SOPRANO KJ: Retinoids and ovarian cancer. ./. Cell. Physiol. (2000) 185:1–20.
   PubMed Web of Science ®Google Scholar
• WELCSH PL, KING MC: BRCA I and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. (2001) 10:705–713.
   PubMed Web of Science ®Google Scholar
• DE PALO G, MARIANI L, CAMERINI T et al.: Effect of fenretinide on ovarian cancer occurrence. Gynecol. Oncol. (2002) 89:24–27.
   Google Scholar
• OZOLS RF, DALY MB, KLEIN-SZANTO A, HAMILTON TC, BAST RC Jr, BREWER MA: Specific keynote: chemoprevention of ovarian cancer: the journey begins. Cynecol Oncol (2003) 88:S67–S70.
   Google Scholar
• RATKO TA, DETRISAC CJ, DINGER NM, THOMAS CF, KELLOFF GJ, MOON RC: Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. (1989) 49:4472–4476.
   PubMed Web of Science ®Google Scholar
• ZUJEWSKI J, PAI L, WAKEFIELD L et al.: Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res. Treat. (1999) 57:277–283.
   PubMed Web of Science ®Google Scholar
• •Clinical exploration of fenretinide as adjunctive or combination therapy for advanced breast cancer.
   Google Scholar
• CONLEY B, O'SHAUGHNESSY J, PRINDIVILLE S et al: Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J. Clin. Oncol (2000) 18:275–283.
   PubMed Web of Science ®Google Scholar
• •Clinical exploration of fenretinide as adjunctive or combination therapy for the control of breast cancer progression.
   Google Scholar
• COBLEIGH MA, GRAY R, GRAHAM M et al.: Fenretinide (FEN) versus placebo in postmenopausal breast cancer patients receiving adjuvant tamoxifen (TAM), an Eastern Cooperative Oncology Group phase III intergoup trial. Proc. AMU. Meet. Am. Soc. Clin. Oncol (2000) 19:0000 (Abstract 328).
   Google Scholar
• ••Phase III study of fenretinide as adjunctiveor combination therapy for control of breast cancer progression.
   Google Scholar
• SINGLETARY E, LIEBERMAN R, ATKINSON N et al: Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N[4-hydroxyphenyll retinamide. Cancer Epidemiol Biomarkers Prey (2000) 9:1087–1090.
   PubMed Web of Science ®Google Scholar
• SINGLETARY SE, ATKINSON EN, HOQUE A et al: Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin. Cancer Res. (2002) 8:2835–2842.
   PubMed Web of Science ®Google Scholar
• ••Results of an initial clinical trial offenretinide for the modulation of biomarkers associated with the prevention of early breast cancer.
   Google Scholar
• BREWER MA, MITCHELL ME BAST RC: Prevention of ovarian cancer. In Vivo (1999) 13:99–106.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ GC, NAGARSHETH NP, LEE KL et al.: Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J. Natl. Cancer Inst. (2002) 94:50–60.
   PubMed Web of Science ®Google Scholar
• BREWER M, UTZINGER U, LI Y et al: Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J. Biomed. Opt. (2002) 7:20–26.
   PubMed Web of Science ®Google Scholar
• FOLLEN M, ATKINSON EN, SCHOTTENFELD D et al: A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin. Cancer Res. (2001) 7:3356–3365.
   PubMed Web of Science ®Google Scholar
• KURIE JM, LEE JS, KHURI FR et al: N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin. Cancer Res. (2000) 6:2973–2979.
   PubMed Web of Science ®Google Scholar
• LOTAN R, LEE JJ, MARTIN J et al: Retinamide activity in retinoid-resistant oral premalignant lesions (OPLS): Translational correlative studies. Proc. AMU. Meet. Am. Soc. Clin. Oncol (2000) 19:0000 (Abstract 1639).
   Google Scholar
• GARAVENTA A, LUKSCH R, LO PICCOLO MS et al: Phase I trial and pharmacokinetics of fenretinide in children with neurobalstoma. Clin. Cancer Res. (2003) 9:2032–2039.
   PubMed Web of Science ®Google Scholar
• •Clinical exploration of dose maximisation strategy for fenretinide in cancer therapy.
   Google Scholar
• JASTI BR, LORUSSO PM, PARCHMENT RE et al.: Phase I clinical trial of fenretinide (N5C374551) in advanced solid tumors. Proc. AMU. Meet. Am. Soc. Clin. Oncol (2001) 20 (Abstract 485).
   Google Scholar
• •Clinical exploration of dose maximisation strategy for fenretinide in cancer therapy.
   Google Scholar
• DOOSE DR, MINN FL, STELLAR S, NAYAK RK: Effects of meals and meal composition on the bioavailability of fenretinide.Pharmacol (1992)32:1089–1095.
   Web of Science ®Google Scholar
• FORMELLI F: Correspondence re: M. Follen et al, a randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin. Cancer Res. (2002) 8:1310–1312.
   Google Scholar
• CLIFFORD JL, SABICHI AL, ZOU C et al: Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prey (2001) 10:391–395.
   PubMed Web of Science ®Google Scholar
• D'AMBROSIO SM, GIBSON-D'AMBROSIO R, MILO GE, CASTO B, KELLOFF GJ, STEELE VE: Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res. (2000) 20:2273–2280.
   PubMed Web of Science ®Google Scholar
• PEREIRA MA: Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs. Adv. Exp. Med. Biol. (1999) 470:55–63.
   PubMed Web of Science ®Google Scholar
• ABOU-ISSA H, CURLEY RW Jr, ALSHAFIE GA et al.: Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis. Anticancer Res. (2001) 21:3839–3844.
   PubMed Web of Science ®Google Scholar
• ABOU-ISSA H, CURLEY RW Jr, PANIGOT MJ, TANAGHO SN, SIDHU BS, ALSHAFIE GA: Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model. Anticancer Res. (1997) 17:3335–3339.
   PubMed Web of Science ®Google Scholar
• MERRITT G, ALIPRANDIS ET, PRADA F, RIGAS B, KASHFI K: The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines. Cancer Lem (2001) 164:15–23.
   PubMed Web of Science ®Google Scholar
• LIM S-J, SIMEONE A-M, KIM C-K, TARI A: Cyclosporin A enhances the apoptotic effects of N-(4-hydroxyphenyl)retinamide in breast cancer cells. Int. J. Cancer (2002) 101:243–247.
   PubMed Web of Science ®Google Scholar
• BRUNO S, TENCA C, SAVERINO D, CICCONE E, GROSSI C: Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis (2002) 23(3):447–456.
   PubMed Web of Science ®Google Scholar
• HAIL M, LOTAN R: Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol Biomarkers Prey (2000) 9:1293–1301.
   PubMed Web of Science ®Google Scholar
• FARIAS E, ARAPSHIAN A, BLEIWEISS I, WAXMAN S, ZELENT A, MIRA-Y-LOPEZ R: Retinoic acid receptor Ot2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ (2002) 13(8):335–341.
   PubMedGoogle Scholar
• ALTUCCI L, GRONEMEYER H: The promise of retinoids to fight against cancer. Nat. Rev Cancer (2001) 1:181–193.
   PubMed Web of Science ®Google Scholar
• SUH Y, LEE H, VIRMANI A et al: Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. (2002) 62(14)3945–3949.
   Google Scholar
• PILI R, KRUSZEWSKI M, HAGER B, LANTZ J, CARDUCCI M: Combination of phenylbutarate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. (2001) 61(4):1477–1485.
   PubMed Web of Science ®Google Scholar
• KURIE JM: The biologic basis for the use of retinoids in cancer prevention and treatment. Curr. Opin. Oncol (1999) 11:497–502.
   PubMedGoogle Scholar
• HANSEN LA, SIGMAN CC, ANDREOLA F, ROSS SA, KELLOFF GJ, DE LUCA LM: Retinoids in chemoprevention and differentiation therapy. Carcinogenesis (2000) 21:1271–1279.
   PubMed Web of Science ®Google Scholar
• LIPPMAN SM, LOTAN R: Advances in the development of retinoids as chemopreventive agents. Num. (2000) 130:479S–482S.
   Google Scholar
• DRAGNEV KH, RIGAS JR, DMITROVSKY E: The retinoids and cancer prevention mechanisms. Oncologist (2000) 5:361–368.
   PubMedGoogle Scholar
• DAS GUPTA TK: Evaluation of rGlutamyltranspeptidase as an Intermediate Endpoint During 7,12- Dimethylbenz(a) anthracene-Induced Buccal Pouch Carcinogenesis in Hamsters. University of Illinois, Chicago, IL, USA (1994) (Contract no. NO1-CN–25492–01).
   Google Scholar
• SILVERMAN J, KATAYAMA S, ZELENAKAS K et al.: Effect of retinoids on the induction of colon cancer in F344 rats by N-methyl-N-nitrosourea or by 1,2-dimethylhydrazine. Carcinogenesis (1981) 2:1167–1172.
   PubMed Web of Science ®Google Scholar
• LI H, KRAMER PM, LUBET RA, STEELE VE, KELLOFF GJ, PEREIRA MA: Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett. (1999) 147:187–193.
   PubMed Web of Science ®Google Scholar
• ZHENG Y, KRAMER PM, LUBET RA, STEELE VE, KELLOFF GJ, PEREIRA MA: Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis (1999) 20:255–260.
   PubMed Web of Science ®Google Scholar
• DAS GUPTA TK: Evaluation of Dysplasia as an Intermediate Endpoint Marker for Lung Carcinogenesis Using the Hamster INP-Implant Model. University of Illinois, Chicago, IL, USA (1995) (Contract no. NO1-CN–25492–02).
   Google Scholar
• McCORMICK DL, JOHNSON WD, RAO KVN et al: Comparative activity of N-(4-hydroxypheny1)-all-trans-retinamide and a-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis (1996) 17:2513–2517.
   PubMed Web of Science ®Google Scholar
• CHAN L-NL, ZHANG S-L, CLOYD M, CHAN T-S: N-(4-Hydroxypheny9retinamide prevents development of T-Lymphomas in AKR/J mice. Anticancer Res. (1997) 17:499–503.
   PubMed Web of Science ®Google Scholar
• RAO GN, NEY E, HERBERT RA: Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene. Breast Cancer Res. Treat. (1999) 58:241–254.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, MEHTA RG, THOMPSON CA, DINGER N, CALD WELL JA, MOON RC: Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyOretinamide and ovariectomy. Cancer Res. (1982) 42:508–512.
   PubMed Web of Science ®Google Scholar
• WELSCH CW, DEHOOG JV, MOON RC: Lack of an effect of dietary retinoids in chemical carcinogenesis of the mouse mammary gland: Inverse relationship between mammary tumor cell anaplasia and retinoid efficacy. Carcinogenesis (1984) 5:1301–1304.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, BECCI PJ, MOON RC: Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride-divinyl ether copolymer (MVE-2). Carcinogenesis (1982) 3:1473–1477.
   PubMed Web of Science ®Google Scholar
• MOON RC, KELLOFF GJ, DETRISAC CJ, STEELE VE, THOMAS CF, SIGMAN CC: Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. (1992) 12:1147–1154.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, MOON RC: Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis (1986) 7:193–196.
   PubMed Web of Science ®Google Scholar
• LUBET RA, STEELE VE, DECOSTER R, et al: Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis (1998) 19:1345–1351.
   PubMed Web of Science ®Google Scholar
• COPE MB, STEELE VE, LUBET R et al: Prevention of mammary cancers by 9-cis-retinoic acid (9-cis-RA) and 4-hydroxyphenylretinamide (4-HPR) either alone or in combination. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 356).
   Google Scholar
• BIRT DF, SAYED S, DAVIES MH, POUR P: Sex differences in the effects of retinoids on carcinogenesis by N-nitroschis(2-oxopropy9amine in Syrian hamsters. Cancer Lett. (1981) 14:13–21.
   PubMedGoogle Scholar
• POLLARD M, LUCKERT PH, SPORN MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxypheny9retinamide. Cancer Res. (1991) 51:3610–3611.
   PubMed Web of Science ®Google Scholar
• OHSHIMA M, WARD JM, WENK ML: Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACl/ segHapBR rats. J. Natl. Cancer Inst. (1985) 74:517–524.
   PubMed Web of Science ®Google Scholar
• WILLE JJ, CHOPRA D, SHEALY YF: Biological evaluation of retinoyl amino acids-suppression of tumor formation and ODC enzyme induction. Proc. AMIE Meet. Am. Assoc. Cancer Res. (1986) 27:146 (Abstract 578).
   Google Scholar
• McCORMICK DL, BAGG BJ, HULTIN TA: Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumor induction in mice. Cancer Res. (1987) 47:5989–5993.
   PubMed Web of Science ®Google Scholar
• McCORMICK DL, MOON RC: Antipromotional activity of dietary N-(4-hydroxyphenyOretinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice. Cancer Lett. (1986) 31:133–138.
   PubMed Web of Science ®Google Scholar